V. Papadimitrakopoulou

Author

The University of Texas MD Anderson Cancer Center

Also Known As

Papadimitrakopoulou V., V PAPADIMITRAKOPOULOU, V Papadimitrakopoulou, V. Papadimitrakopoulou, VA Papadimitrakopoulou

Publications

874

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center AstraZeneca (United Kingdom)Spectrum Pharmaceuticals (United States)Princess Margaret Cancer Centre

About

V. Papadimitrakopoulou is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	498
2	Pathology	9	9	271
3	Health Sciences	6	6	200
4	Pharmacology	5	5	83
5	Cell Biology	3	3	141

V. Papadimitrakopoulou

Publications

707

Citations

H-Index

Page 1

	Year	Citations
Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy Li Mao, V. Papadimitrakopoulou, Dong M. Shin, JNCI Journal of the National Cancer Institute	1998	167
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results R. Komaki, Lee J.S., B. Kaplan, Seminars in Radiation Oncology MedicineMetronomic TherapyPreliminary ResultsBronchial NeoplasmPhase Iii Study	2002	95
OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) John V. Heymach, Marcelo V. Negrão, Jacqulyne Robichaux, Journal of Thoracic Oncology MedicinePathologyCancer TreatmentCancer GeneticsRadiation Oncology	2018	86
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma Erminia Massarelli, Heather Lin, Lawrence E. Ginsberg, Annals of Oncology Phase Ii TrialMedicineHead And Neck CancerDermatologyCancer Treatment	2015	85
The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis V. Papadimitrakopoulou, Eleanor Brown, Dandan Liu, Cancer Letters Prognostic RoleMedicinePathologyNeck CarcinogenesisHead And Neck Cancer	2005	40
191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC Solange Peters, Scott Antonia, Sarah B. Goldberg, Journal of Thoracic Oncology Durvalumab MonotherapyCancer TherapeuticsMedicineClinical TrialsTremelimumab Combination Therapy	2016	35
A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results V. Papadimitrakopoulou, G. R. Blumenschein, N. B. Leighl, Journal of Clinical Oncology	2008	31
Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) M.S. Kies, Adam S. Garden, V. Papadimitrakopoulou, Journal of Clinical Oncology Surgical OncologyNeoadjuvant TherapySquamous Cell CarcinomaCancer ManagementPathology	2006	30
Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI) Yi‐Long Wu, Tony Mok, Myung‐Ju Ahn, Annals of Oncology Egfr T790mOverall SurvivalMedicinePathologyBronchial Neoplasm	2019	29
A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) V. Papadimitrakopoulou, J.C. Soria, Jean‐Yves Douillard, Journal of Clinical Oncology PathologyPhase Ii StudyPharmacotherapyVivo Nsclc ModelsOncology	2007	26

Page 1